The combined panel of HOXA9 + HIC1 and HIC1 + SOX1 exhibited the best discriminatory efficiencies at all stages of ovarian cancer (100.0% (10/10) of stage I/II, 80.0% (24/30) and 70.0% (21/30) of stage III, respectively and 80.0% (4/5) and 100.0% (5/5) of stage IV of ovarian cancer, respectively). This evidence concerns the gene HOXA9 and ovarian carcinoma.